If you've been paying any attention along the way, you'd know that today is the first major step in the commercialization process. You seem to want step #3 to occur before step #1, so you'll constantly be disappointed in things with that outlook. Let's see CLIA get underway, announcement of positive data, and then the BP partner will come on board.
Also, there is absolutely no evidence of "big dilution" coming after the proxy as you fear. That's an interesting concern of yours since you previously posted "First of all, Amarantus is now in a much better position than a year ago, access to cash through LPC, Lympro is much more advanced, Eltoprazine etc." Save the "big dilution" garbage for the other message boards.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links
NextEra Energy's Ambitious Fundraising PlansUtility giant NextEra Energy (NYSE: NEE) has announced its intention to raise a significant $1.5 billion through the sale of equity units. This funding is crucial as it aims to support various energy projects that are aligned with the company's long-term growth strategy.Meeting Growing Energy DemandThe push for increased investment comes at a time when utility companies across the nation are gearing up to meet a surge in ene... Continue Reading
International Media Acquisition Corp Announces Merger Deadline ExtensionIn a recent filing with the Securities and Exchange Commission, International Media Acquisition Corp. (IMAQ) has taken a significant step by extending the deadline for its initial business combination. The deadline has been moved from November 2, 2024, to December 2, 2024.This strategic extension involves a deposit of $20,000 into the company’s trust account, termed the "Extension Payment." This measure is... Continue Reading
CareMax Extends Waiver on Credit Agreement DefaultsCareMax, Inc. (NASDAQ:CMAX), a leading healthcare provider focused on nursing and personal care facilities, has successfully negotiated an extension with its lenders regarding the waiver of certain defaults in its credit agreement. This extension, announced recently, will be in effect until November 4, 2024, although it could be terminated earlier under certain conditions.Details of the Credit AgreementThe initial agr... Continue Reading
Dream Finders Homes Acquires Alliant National Title Insurance Company
In a strategic move reflecting the ongoing consolidation in the real estate services industry, Alliant National Title Insurance Company has officially announced its acquisition by Dream Finders Homes, Inc. (NYSE: DFH). This agreement represents a pivotal milestone for both companies, further solidifying Dream Finders Homes’ presence in the market.
Alliant National, previously owned by Presidio Investors sinc... Continue Reading
Windtree Therapeutics Considers New Financial Options
Windtree Therapeutics Inc. (NASDAQ:WINT), a company at the forefront of biotechnology, has recently provided insight into its financial maneuvers through an 8-K filing with the Securities and Exchange Commission (SEC). The firm announced a prospectus supplement that outlines the potential sale of up to $27,243,504 worth of common stock to Seven Knots, LLC. This comes from a previously established equity line of credit, allowing Wi... Continue Reading
EyePoint Pharmaceuticals Unveils New $100 Million Stock Offering
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a dynamic biopharmaceutical company devoted to innovative solutions for serious retinal diseases, recently disclosed a substantial public offering aimed at raising a staggering $100 million. The offering will additionally grant underwriters a valuable 30-day option to acquire an extra $15 million of stock at the public offering price, minus the customary underwriting discou... Continue Reading
FutureTech II Faces Delisting DilemmaFutureTech II Acquisition Corp. is currently facing significant challenges that could lead to its delisting from The Nasdaq Global Market. The company received notice regarding its Market Value of Listed Securities (MVLS), which has dipped below the Nasdaq's minimum requirement of $50 million for a prolonged period of 30 consecutive business days.Background on the Compliance WarningThe initial compliance warning from Nasdaq was iss... Continue Reading
Alimetry Raises $18 Million to Transform Gut Health Diagnostics
Alimetry has recently secured an impressive $18 million in an oversubscribed financing round aimed at advancing its revolutionary wearable device designed for gut health diagnostics. This significant investment comes as the company experiences increased adoption from hospitals, fueled by its latest achievements, including a fourth FDA clearance and the establishment of a new reimbursement code. With a focus on improving ... Continue Reading
Symbotic to Reveal Financial Outcomes for Q4 and Fiscal Year 2024Symbotic Inc. (NASDAQ: SYM), a frontrunner in the A.I.-driven robotic technology space for supply chain solutions, is gearing up to announce its fourth quarter and fiscal year 2024 financial results. This much-anticipated update will occur after the market closes on a soon-to-be-specified date in November. Investors are eager to see how the company’s innovative strategies have paid off over the past fiscal year.... Continue Reading
Important Deadline for Allarity Therapeutics Investors
Many investors are eagerly watching for developments regarding Allarity Therapeutics, Inc. This situation became urgent with the approaching deadline for filing lead plaintiff motions in a class action lawsuit involving investors who acquired Allarity securities. This class action covers transactions made between specific dates, reflecting the challenges faced by the company and its stakeholders.
Understanding the Class ... Continue Reading